FaDu In Vitro Reporter Gene (β-glucuronidase) Assay

This assay is to provide FaDu-based In Vitro Reporter Gene (β-glucuronidase) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

FaDu

Human

FaDu is a cell line with epithelial morphology that was established in 1968 from a punch biopsy of a hypopharyngeal tumor removed from a 56-year-old, White, male patient with squamous cell carcinoma. This cell line is a suitable transfection host and has applications in cancer and immuno-oncology research.

Squamous Cell Carcinoma

Oncology

In Vitro Reporter Gene (β-glucuronidase) Assay

FaDu-cell based In Vitro Reporter Gene (β-glucuronidase) Assay

Reporter gene assays have become a valuable technique for studying gene expression by both cis- and trans-acting regulatory factors. The action of a reporter gene is evaluated in a reporter gene assay and a reporter gene construct normally comprises of a target regulatory DNA sequence (usually a major in a cancer pathway) to be analyzed, sequence for the reported gene and a sequence for functional mRNA in an expression vector. The expression vector can be transfected into the desired cell type. After transfection of the vector, the effects on a drug on the expression of target gene can be evaluated. The ideal reported gene activity should detect with high sensitivity over any endogenous gene expression. Reporter gene systems permit the use of cancer pathway-specific or developmentally regulated regulatory DNA sequences as markers to analyze gene expression in specific pathways associated with molecular mechanisms of cancer.

β-glucuronidase

High-throughput Screening, High Content Screening and Reporter Gene Assays